Pillstats
Rx only · Injection, Solution · Intra-Articular

Dexamethasone Sodium Phosphate

Dexamethasone Sodium Phosphate

12 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US36 NDCs
12 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCA01AC02
RxCUI (US)3264
US makers12 labelers
Packages37
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 7 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.206$0.411$0.617$0.823Dec 2025Apr 2026Jul 2026
$0.591
Latest avg · Jul 22, 2026
+16%
Since Dec 17, 2025
12
Active US suppliers
35%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

37K74K111K148K2025 Q12025 Q22025 Q32025 Q42026 Q1
93K
Rx · 2026 Q1
347K
Units dispensed
-28%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it12 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Medical Purchasing Solutions, LLCunknown7SUPPLYING
Mylan Institutional LLCunknown6SUPPLYING
Asclemed USA, Inc.unknown5SUPPLYING
A-S Medication Solutionsunknown4SUPPLYING
Eugia US LLCunknown3SUPPLYING
Sagent Pharmaceuticalsunknown3SUPPLYING
Amneal Pharmaceuticals LLCunknown3SUPPLYING
ProPharma Distributionunknown2SUPPLYING
Fresenius Kabi USA, LLCunknown1SUPPLYING
REMEDYREPACK INC.repackager1SUPPLYING
Henry Schein Inc.unknown1SUPPLYING
HF Acquisition Co LLC, DBA HealthFirstunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • May 23, 2024
    RECALLRecall (Class II): Dexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only, Distributed b…

    Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec. — Recalling firm: Eugia US LLC — USA Nationwide

  • Feb 8, 2019
    SHORTAGEDrug shortage: Dexamethasone Sodium Phosphate Injection (Mylan Institutional, a Viatris Company)

    Dexamethasone Sodium Phosphate Injection — reported in shortage by Mylan Institutional, a Viatris Company. Therapeutic category: Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology.